136 related articles for article (PubMed ID: 15914206)
1. Spontaneous and mutagen-induced loss of DNA mismatch repair in Msh2-heterozygous mammalian cells.
Borgdorff V; van Hees-Stuivenberg S; Meijers CM; de Wind N
Mutat Res; 2005 Jul; 574(1-2):50-7. PubMed ID: 15914206
[TBL] [Abstract][Full Text] [Related]
2. Mouse models for hereditary nonpolyposis colorectal cancer.
de Wind N; Dekker M; van Rossum A; van der Valk M; te Riele H
Cancer Res; 1998 Jan; 58(2):248-55. PubMed ID: 9443401
[TBL] [Abstract][Full Text] [Related]
3. Selective radiosensitization of drug-resistant MutS homologue-2 (MSH2) mismatch repair-deficient cells by halogenated thymidine (dThd) analogues: Msh2 mediates dThd analogue DNA levels and the differential cytotoxicity and cell cycle effects of the dThd analogues and 6-thioguanine.
Berry SE; Davis TW; Schupp JE; Hwang HS; de Wind N; Kinsella TJ
Cancer Res; 2000 Oct; 60(20):5773-80. PubMed ID: 11059773
[TBL] [Abstract][Full Text] [Related]
4. MSH2 deficiency contributes to accelerated APC-mediated intestinal tumorigenesis.
Reitmair AH; Cai JC; Bjerknes M; Redston M; Cheng H; Pind MT; Hay K; Mitri A; Bapat BV; Mak TW; Gallinger S
Cancer Res; 1996 Jul; 56(13):2922-6. PubMed ID: 8674041
[TBL] [Abstract][Full Text] [Related]
5. Mouse mismatch repair gene Msh2 is not essential for transcription-coupled repair of UV-induced cyclobutane pyrimidine dimers.
Sonneveld E; Vrieling H; Mullenders LH; van Hoffen A
Oncogene; 2001 Jan; 20(4):538-41. PubMed ID: 11313985
[TBL] [Abstract][Full Text] [Related]
6. DNA mismatch repair deficiency stimulates N-ethyl-N-nitrosourea-induced mutagenesis and lymphomagenesis.
Claij N; van der Wal A; Dekker M; Jansen L; te Riele H
Cancer Res; 2003 May; 63(9):2062-6. PubMed ID: 12727820
[TBL] [Abstract][Full Text] [Related]
7. Methylation tolerance in mismatch repair proficient cells with low MSH2 protein level.
Claij N; Te Riele H
Oncogene; 2002 Apr; 21(18):2873-9. PubMed ID: 11973647
[TBL] [Abstract][Full Text] [Related]
8. Msh2 DNA mismatch repair gene deficiency and the food-borne mutagen 2-amino-1-methy1-6-phenolimidazo [4,5-b] pyridine (PhIP) synergistically affect mutagenesis in mouse colon.
Zhang S; Lloyd R; Bowden G; Glickman BW; de Boer JG
Oncogene; 2001 Sep; 20(42):6066-72. PubMed ID: 11593414
[TBL] [Abstract][Full Text] [Related]
9. Msh-2 suppresses in vivo mutation in a gene dose and lesion dependent manner.
Sansom OJ; Toft NJ; Winton DJ; Clarke AR
Oncogene; 2001 Jun; 20(27):3580-4. PubMed ID: 11429706
[TBL] [Abstract][Full Text] [Related]
10. Base transitions dominate the mutational spectrum of a transgenic reporter gene in MSH2 deficient mice.
Andrew SE; Reitmair AH; Fox J; Hsiao L; Francis A; McKinnon M; Mak TW; Jirik FR
Oncogene; 1997 Jul; 15(2):123-9. PubMed ID: 9244348
[TBL] [Abstract][Full Text] [Related]
11. Evidence for Msh2 haploinsufficiency in mice revealed by MNU-induced sister-chromatid exchange analysis.
Bouffler SD; Hofland N; Cox R; Fodde R
Br J Cancer; 2000 Nov; 83(10):1291-4. PubMed ID: 11044352
[TBL] [Abstract][Full Text] [Related]
12. A role for mismatch repair in control of DNA ploidy following DNA damage.
Strathdee G; Sansom OJ; Sim A; Clarke AR; Brown R
Oncogene; 2001 Apr; 20(15):1923-7. PubMed ID: 11313940
[TBL] [Abstract][Full Text] [Related]
13. Functional analysis of HNPCC-related missense mutations in MSH2.
Lützen A; de Wind N; Georgijevic D; Nielsen FC; Rasmussen LJ
Mutat Res; 2008 Oct; 645(1-2):44-55. PubMed ID: 18822302
[TBL] [Abstract][Full Text] [Related]
14. The mammalian mismatch repair protein MSH2 is required for correct MRE11 and RAD51 relocalization and for efficient cell cycle arrest induced by ionizing radiation in G2 phase.
Franchitto A; Pichierri P; Piergentili R; Crescenzi M; Bignami M; Palitti F
Oncogene; 2003 Apr; 22(14):2110-20. PubMed ID: 12687013
[TBL] [Abstract][Full Text] [Related]
15. Cell lineage-specific effects associated with multiple deficiencies of tumor susceptibility genes in Msh2(-/-)Rb(+/-) mice.
Nikitin AY; Liu CY; Flesken-Nikitin A; Chen CF; Chen PL; Lee WH
Cancer Res; 2002 Sep; 62(18):5134-8. PubMed ID: 12234974
[TBL] [Abstract][Full Text] [Related]
16. Tumors arising in DNA mismatch repair-deficient mice show a wide variation in mutation frequency as assessed by a transgenic reporter gene.
Baross-Francis A; Milhausen MK; Andrew SE; Jevon G; Jirik FR
Carcinogenesis; 2000 Jun; 21(6):1259-62. PubMed ID: 10837019
[TBL] [Abstract][Full Text] [Related]
17. Msh2 deficiency increases the mutation frequency in all parts of the mouse colon.
Zhang S; Lloyd R; Bowden G; Glickman BW; de Boer JG
Environ Mol Mutagen; 2002; 40(4):243-50. PubMed ID: 12489114
[TBL] [Abstract][Full Text] [Related]
18. Mechanisms of pathogenicity in human MSH2 missense mutants.
Ollila S; Dermadi Bebek D; Jiricny J; Nyström M
Hum Mutat; 2008 Nov; 29(11):1355-63. PubMed ID: 18951462
[TBL] [Abstract][Full Text] [Related]
19. DNA mismatch repair proteins promote apoptosis and suppress tumorigenesis in response to UVB irradiation: an in vivo study.
Young LC; Thulien KJ; Campbell MR; Tron VA; Andrew SE
Carcinogenesis; 2004 Oct; 25(10):1821-7. PubMed ID: 15166087
[TBL] [Abstract][Full Text] [Related]
20. Deregulation of homologous recombination DNA repair in alkylating agent-treated stem cell clones: a possible role in the aetiology of chemotherapy-induced leukaemia.
Worrillow LJ; Allan JM
Oncogene; 2006 Mar; 25(12):1709-20. PubMed ID: 16278672
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]